Teva Pharmaceutical Industries (TEVA) FCF Margin: 2009-2025
Historic FCF Margin for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Sep 2025 value amounting to 5.20%.
- Teva Pharmaceutical Industries' FCF Margin fell 738.00% to 5.20% in Q3 2025 from the same period last year, while for Sep 2025 it was 3.45%, marking a year-over-year decrease of 471.00%. This contributed to the annual value of 4.53% for FY2024, which is 79.00% down from last year.
- According to the latest figures from Q3 2025, Teva Pharmaceutical Industries' FCF Margin is 5.20%, which was up 65.79% from 3.14% recorded in Q2 2025.
- Over the past 5 years, Teva Pharmaceutical Industries' FCF Margin peaked at 23.89% during Q4 2023, and registered a low of -13.94% during Q1 2021.
- In the last 3 years, Teva Pharmaceutical Industries' FCF Margin had a median value of 3.14% in 2025 and averaged 3.35%.
- Per our database at Business Quant, Teva Pharmaceutical Industries' FCF Margin plummeted by 1,800bps in 2021 and then surged by 1,632bps in 2024.
- Over the past 5 years, Teva Pharmaceutical Industries' FCF Margin (Quarterly) stood at 7.39% in 2021, then skyrocketed by 1,401bps to 21.40% in 2022, then skyrocketed by 250bps to 23.89% in 2023, then slumped by 1,335bps to 10.55% in 2024, then slumped by 738bps to 5.20% in 2025.
- Its FCF Margin was 5.20% in Q3 2025, compared to 3.14% in Q2 2025 and -5.96% in Q1 2025.